Unilever to acquire Fluocaril and Parogencyl brands from Procter & Gamble

Unilever
Add to MyMedicalExpo favorites

LONDON, UK/ROTTERDAM, Netherlands: Unilever has announced that it has signed an agreement to acquire the Fluocaril and Parogencyl oral care brands from Procter & Gamble.

Fluocaril and Parogencyl are well-known therapeutic brands sold in the pharmaceutical industry, primarily in France and Spain. They have a product portfolio that is widely endorsed by health professionals. Fluocaril offers oral care solutions specialising in protection against dental caries. Parogencyl tackles gingival issues.

The acquisition will give Unilever a leading role in oral care in the pharmaceutical industry in France, as well as a strong position in Spain. With their powerful brand heritage, high visibility and sound reputation with dentists, these brands are a great complement to the existing oral care portfolio of Unilever.

The terms of the deal were not disclosed. The acquisition is expected to close in the second quarter of 2019.

Through the acquisition, Unilever aims to strengthen its position in the oral care industry in Europe. (Photograph: Piotr Swat/Shutterstock)
 

Through the acquisition, Unilever aims to strengthen its position in the oral care industry in Europe. (Photograph: Piotr Swat/Shutterstock)